In the diabetic subgroup, GLP‐1 agonists decreased the RR of developing stroke (RR 0.85, 95% CI 0.78−0.92) but the association for MI was marginally nonsignificant (RR 0.90, 95% CI 0.80−1.01, I2 = 42%). The gene discussed is GLP1R; the disease is stroke disorder.